Showing results (2081-2090 of 2,239) with videos related to
Sort By:
Pageof 224
The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.Journal of Thoracic Disease|October 23, 2023
Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancerShi-Ling Zhang, Chan-Yuan Zhang, Yu-Qing Chen, et al.The Journal of Infection|June 15, 2020
Imported dengue serotype 1 outbreak in a non-endemic region, China, 2017: A molecular and seroepidemiological studyMing-Xiao Yao, Shu-Zhi Wu, Guo-Lin Wang, et al.The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.JAMA Oncology|September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical TrialLeora Horn, Ziping Wang, Gang Wu, et al.Cell Death & Disease|October 12, 2018
Degranulation of mast cells induced by gastric cancer-derived adrenomedullin prompts gastric cancer progressionYi-Pin Lv, Liu-Sheng Peng, Qi-Hong Wang, et al.Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.Bioorganic & Medicinal Chemistry Letters|October 26, 2005
Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffoldWayne D Vaccaro, Rosy Sher, Michael Berlin, et al.Cancer Cell|February 5, 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLCAlexa B Turke, Kreshnik Zejnullahu, Yi-Long Wu, et al.Lung Cancer (Amsterdam, Netherlands)|March 31, 2026
Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancerJun-Tao Lin, Xue-Ning Yang, Xiang-Meng Li, et al.Pageof 224